Phase 1RecruitingPriority 4 · Lower priorityNCT07164560
Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma
Plain-language summary
This trial is testing Anti-TRBC1 CAR-T cells for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 1 trial, which means researchers are finding the right dose and this is among the earliest testing in patients. The study looks at both safety and how well the treatment controls the lymphoma. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years to 75 Years years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Anti-TRBC1 CAR-T cells (BIOLOGICAL): Umbilical cord blood-derived NK cells transduced with lentiviral vector express anti-TRBC1 CAR
Anti-TRBC1 CAR-T cells
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details